Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations

Journal of Clinical Microbiology

Volumn 43, Issue 6, 2005, Pages 2991-2993

  Romanò, Luisa ^a   Velati, Claudio ^b,d   Baruffi, Lorella ^b   Fomiatti, Laura ^b   Colucci, Giuseppe ^c   Zanetti, Alessandro R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Hospital of Sondrio   (Italy)

^c Scientific Affairs   (Switzerland)

^d Ospedale Civile   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DNA DETERMINATION; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; STANDARDIZATION;

BLOOD DONORS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

EID: 20444474541     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.6.2991-2993.2005     Document Type: Article

References (18)

1. Allain, J. P. 2003. Transfusion risks of yesterday and of today. Transfus. Clin. Biol. 10:1-5.
2. Alvarez, M., S. Oyonarte, P. M. Rodriguez, and J. M. Hernandez. 2002. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 42:994-998.
3. Busch, M. P., S. H. Kleinman, and G. J. Nemo. 2003. Current and emerging infectious risks of blood transfusions. JAMA 289:959-962.
4. DiDomenico, N., H. Link, R. Knobel, T. Caratsch, W. Weschler, Z. G. Loewy, and M. Rosenstraus. 1996. COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine PCR. Clin. Chem. 42:1915-1923.
5. Dodd, R. Y., E. P. Notari IV, and S. L. Stramer. 2002. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42:975-979.
6. Glynn, S. A., S. H. Kleinman, D. J. Wright, M. P. Busch, and the NHLBI Retrovirus Epidemiology Donor Study. 2002. International application of the incidence rate/window period model. Transfusion 42:966-972.
7. Kleinman, S., M. P. Busch, J. J. Korelitz, and G. B. Schreiber. 1997. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus. Med. Rev. 11:155-172.
8. International Forum. 2002. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. Vox Sang. 82:87-111.
9. Jungkind, D., S. Direnzo, K. G. Beavis, and N. S. Silverman. 1996. Evaluation of automated COBAS AMPLICOR PCR system for detection of several infectious agents and its impact on laboratory management. J. Clin. Microbiol. 34:2778-2783.
10. Lackritz, E. M., G. A. Satten, J. Aberle-Grasse, R. Y. Dodd, V. P. Raimondi, R. S. Janssen, W. F. Lewis, E. P. Notari, and L. R. Petersen. 1995. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N. Engl. J. Med. 333:1721-1725.
11. Minegishi, K., A. Yoshikawa, S. Kishimoto, H. Yugi, N. Yokoya, M. Sakurada, H. Kiyokawa, K. Nishioka, and Japanese Red Cross NAT Screening Research Group. 2003. Superiority of minipool nucleic acid amplification technology hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang. 84:287-291.
12. Pillonel, J., S. Laperche, C. Saura, J. C. Desenclos, A. M. Couroucè, and Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. 2002. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 42:980-988.
13. Sato, S., W. Ohhashi, H. Ihara, S. Sakaya, T, Kato, and H. Ikeda. 2001. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion 41:1107-1113.
14. Schreiber, G. B., M. P. Busch, S. H. Kleinman, J. J. Korelitz, and the NHLBI Retrovirus Epidemiology Blood Donor Study. 1996. The risk of transfusion-transmitted viral infections. N. Engl. J. Med. 11:155-172.
15. Seed, C. R., Cheng, A., S. L. Ismay, W. V. Bolton, P. Kiely, T. J. Cobain, A. J. Keller, and Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service. 2002. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 42:1365-1372.
16. Sun, R., W. Schilling, H. Jayakar, J. Ku, J. Wang, M. Rosenstraus, and J. Spadoro. 1999. Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood. Transfusion 39:1111-1119.
17. Velati, C., L. Romanò, L. Baruffi, M. Pappalettera, V. Carreri, and A. R. Zanetti. 2002. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 42:989-993.
18. Velati, C., L. Baruffi, L. Romanò, L. Fomiatti, V. Carreri, A. Zanetti, and the Italian Group for the Study of Transfusion Transmissible Diseases. 2003. The introduction of a NAT method of screening blood donors in Italy: a report of the first two year's experience and a re-evaluation of residual risk. Blood Transfus. 4:368-378.